News and Media Purdue Pharma Statement to 60 Minutes Regarding the Segment on Opioid Medicines Expected to Air Sunday, February 24, 2019 In 1995, the U.S. Food and Drug Administration (FDA) approved OxyContin® (oxycodone HCl) extended-release tablets CII...
News and Media Patients Who Receive Information About the Importance of Safe Disposal Are Three Times More Likely to Dispose of Unused Prescription Opioid Medications Survey study sponsored by Purdue Pharma and published in the Journal of Pain...
News and Media Purdue Pharma L.P. and Alivio Therapeutics Enter into Partnership to Advance ALV-107, a Non-Opioid Interstitial Cystitis/Bladder Pain Syndrome Treatment Alivio to receive up to $14.75 million in upfront and near-term license exercise payments and...
News and Media Purdue Pharma L.P. and Ocular Therapeutix, Inc. Announce Initiation of Collaborative Research Activities to Evaluate Innovative Formulations for Non-Opioid Treatments for Pain Partners to research novel targets for reductions in pain...
News and Media Purdue Pharma L.P. Enters into Exclusive Option Agreement to Acquire SpineThera, Inc. and Its Non-Opioid Product in Development for Epidural Steroid Injection for the Treatment of Low Back Pain Purdue will support SpineThera’s clinical...
STAMFORD, Conn. – September 24, 2018 – Marcelo E. Bigal MD, Ph.D. Chief Medical Officer, Purdue Pharma L.P., issued the following statement today: The nation’s opioid crisis is a significant and urgent public health challenge, and Purdue Pharma is...
Please read carefully the Purdue Pharma L.P. Privacy Policy (the “Privacy Policy”), which is part of the Purdue Pharma L.P. Terms and Conditions, before you access, download, or otherwise use any of our websites, related other parties’ websites, mobile applications, or any electronic service (collectively, the “Service”). This Privacy Policy describes the information collected through Your use of the Service, how we use it, how we share it, how we protect it, and the choices You can make about Your information.
